「Gsk cnbc」熱門搜尋資訊

Gsk cnbc

「Gsk cnbc」文章包含有:「GSKplc」、「GSK-GB:GSKplc」、「GSK.L:GSKplc」、「GLAXO-IN」、「GLAXF:GSKplc」、「GS71-DE:GSKplc」、「GSKsuesPfizerclaimingRSVvaccinepatentinfringement」、「RSVvaccine」、「RSVvaccineuptakewillstartslowerthanshinglesshot」

查看更多
Provide From Google
GSK plc
GSK plc

https://www.cnbc.com

Get GSK plc (GSK:NYSE) real-time stock quotes, news, price and financial information from CNBC.

Provide From Google
GSK-GB: GSK plc
GSK-GB: GSK plc

https://www.cnbc.com

Get GSK plc (GSK-GB:London Stock Exchange) real-time stock quotes, news, price and financial information from CNBC.

Provide From Google
GSK.L: GSK plc
GSK.L: GSK plc

https://www.cnbc.com

GSK plc is a global biopharma company. The Company's segments include Commercial Operations and Research and Development. It develops cancer medicines for ...

Provide From Google
GLAXO-IN
GLAXO-IN

https://www.cnbc.com

Get GlaxoSmithKline Pharmaceuticals Ltd (GLAXO-IN:National Stock Exchange of India) real-time stock quotes, news, price and financial information from CNBC.

Provide From Google
GLAXF: GSK plc
GLAXF: GSK plc

https://www.cnbc.com

Get GSK plc (GLAXF:OTCPK) real-time stock quotes, news, price and financial information from CNBC.

Provide From Google
GS71-DE: GSK plc
GS71-DE: GSK plc

https://www.cnbc.com

Get GSK plc (GS71-DE:XETRA) real-time stock quotes, news, price and financial information from CNBC.

Provide From Google
GSK sues Pfizer claiming RSV vaccine patent infringement
GSK sues Pfizer claiming RSV vaccine patent infringement

https://www.cnbc.com

GlaxoSmithKline sued Pfizer in U.S. court, alleging patent infringement over GSK's respiratory syncytial virus vaccine.

Provide From Google
RSV vaccine
RSV vaccine

https://www.cnbc.com

The Food and Drug Administration approved GSK's RSV vaccine for adults ages 60 and older. · The GlaxoSmithKline shot is now the world's first ...

Provide From Google
RSV vaccine uptake will start slower than shingles shot
RSV vaccine uptake will start slower than shingles shot

https://www.cnbc.com

GlaxoSmithKline CEO Emma Walmsley said she expects uptake for the company's newly approved RSV vaccine to start off slower than it did for ...